Please login to the form below

Not currently logged in
Email:
Password:

Europe pharma stocks take fall

European stocks have fallen today in the wake of drug test failures announced by Actelion and AstraZeneca

European stocks have fallen today in the wake of drug test failures announced by both Actelion and AstraZeneca.

Europe's largest biotech Actelion fell 8 per cent after its haemorrhage drug clazosentan failed in a late-stage study, lessening the chances of it making it to market.

AstraZeneca lost 1.5 per cent after the company's experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to its oncology pipeline.

"We've seen a bit of a pause for breath today and it seems like the market is running out of a bit of steam," said Joshua Raymond, markets strategist at City Index.

27th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics